Endocyte, Inc. (NASDAQ:ECYT) Files An 8-K Results of Operations and Financial ConditionITEM 2.02 Results of Operations and Financial Condition.
On November 7, 2018, Endocyte, Inc. (the “Company”) announced its results of operations for the three months ended September 30, 2018. A copy of the Company’s earnings release is furnished herewith as Exhibit 99.1.
The information in this Item 2.02 and in Item 9.01 of this Current Report (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 2.02 and in Item 9.01 of this Current Report (including Exhibit 99.1) shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01 Financial Statements and Exhibits.
A copy of the Company’s earningsrelease is furnished, but not filed, as Exhibit 99.1 hereto.
Press release issued on November 7, 2018